AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly secured over RMB 200 million in a Series A financing round. The round was led by Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), Huajin Investment, and Huajin Dadao Investment, with participation from Cowin Capital, Wenzhou Capital, and other investors. The funds raised will be directed towards the pre-clinical and clinical development of AnDiConBio’s core product pipelines, with a particular focus on the in-house developed Category 1 influenza therapy ADC189. Notably, the China commercialization rights for ADC189 are exclusively owned by Simcere.
AnDiConBio’s product pipeline encompasses a range of treatments, including ADC789, which targets respiratory syncytial virus (RSV), ADC101, a novel antibiotic for mycoplasma, and others. Additionally, the company is developing ADC308 for the treatment of endometriosis and uterine fibroids.- Flcube.com
